SPoT Coffee (CVE:SPP) Hits New 1-Year Low at $0.04

Share on StockTwits

SPoT Coffee Ltd (CVE:SPP)’s share price hit a new 52-week low on Friday . The company traded as low as C$0.04 and last traded at C$0.04, with a volume of 10000 shares traded. The stock had previously closed at C$0.04.

The company has a market cap of $4.71 million and a P/E ratio of -5.63. The stock’s fifty day moving average price is C$0.04 and its two-hundred day moving average price is C$0.07.

SPoT Coffee Company Profile (CVE:SPP)

Spot Coffee (Canada) Ltd. designs, builds, operates, and franchises community-oriented cafés in Canada and the United States. The company's cafes provide meals and in-house roasted gourmet coffee. It operates a total of 26 cafés in development or under construction, which include 6 corporate-owned cafés located in Buffalo, Rochester, Saratoga Springs, and Glens Falls; 6 operating franchise cafés in Orchard Park, Kenmore, Hamburg, Clarence, Williamsville, and Waterfront Village; 5 Express cafés operating under license to Dash's Supermarkets and to Chartwells at the Buffalo State College; and 9 franchise locations being developed and under construction.

Recommended Story: Key terms to understand channel trading

Receive News & Ratings for SPoT Coffee Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPoT Coffee and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: Onespan Inc  Director Sells $1,056,000.00 in Stock
Insider Selling: Onespan Inc Director Sells $1,056,000.00 in Stock
Hurricane Energy  Stock Rating Lowered by Morgan Stanley
Hurricane Energy Stock Rating Lowered by Morgan Stanley
Zacks Investment Research Downgrades Clinigen Group  to Sell
Zacks Investment Research Downgrades Clinigen Group to Sell
Capgemini’s  “Buy” Rating Reiterated at Societe Generale
Capgemini’s “Buy” Rating Reiterated at Societe Generale
Canadian Western Bank  PT Raised to $23.00
Canadian Western Bank PT Raised to $23.00
Basilea Pharmaceutica  Stock Rating Upgraded by Zacks Investment Research
Basilea Pharmaceutica Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2020 Zolmax.